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The updated international consensus criteria for definite antiphospholipid syndrome (APS)
are useful for scientific clinical studies. However, there remains a need for diagnostic criteria
for routine clinical use. We audited the results of routine antiphospholipid antibodies (aPLs)
in a cohort of 193 consecutive patients with aPL positivity-based testing for lupus anticoagu-
lant (LA), IgG and IgM anticardiolipin (aCL) and anti-ß2glycoprotein-1 antibodies (aß2GPI).
Medium/high-titre aCL/ab2GPI was defined as >99th percentile. Low-titre aCL/ab2GPI posi-
tivity (>95
th<99
th percentile) was considered positive for obstetric but not for thrombotic
APS. One hundred of the 145 patients fulfilled both clinical and laboratory criteria for definite
APS. Twenty-six women with purely obstetric APS had persistent low-titre aCL and/or
ab2GPI. With the inclusion of these patients, 126 of the 145 patients were considered to
have APS. Sixty-seven out of 126 patients were LA-negative, of whom 12 had aCL only, 37
had ab2GPI only and 18 positive were for both. The omission of aCL or ab2GPI testing from
investigation of APS would have led to a failure to diagnose APS in 9.5% and 29.4% of
patients, respectively. Our data suggest that LA, aCL and ab2GPI testing are all required for
the accurate diagnosis of APS and that low-titre antibodies should be included in the diagnosis
of obstetric APS. Lupus (2013) 22, 18–25.
Introduction
The antiphospholipid syndrome (APS) is character-
ized by thrombotic and/or pregnancy morbidity
associated with the presence of persistent antipho-
spholipid antibodies (aPLs).
1 There are many other
clinical manifestations associated with persistent
aPL (including immune thrombocytopenia, livedo
reticularis, migraine, valvular heart disease and
cognitive dysfunction), and, while these conditions
are not considered diagnostic for APS, they are fre-
quently encountered and require clinical attention.
The updated international consensus (Sydney)
classiﬁcation (ICS) criteria for deﬁnite antipho-
spholipid syndrome
1 require the presence of a
lupus anticoagulant (LA) and/or IgG or IgM antic-
ardiolipin antibodies (aCL) present in medium or
high titre (i.e. >40GPL or MPL or >99
th percent-
ile), and/or anti-b2glycoprotein-1 (ab2GPI) (IgG
and/or IgM) >99
th percentile. These aPL should
be persistent, deﬁned as being present on two
or more consecutive occasions at least 12 weeks
apart. The international consensus criteria were ori-
ginally designed for scientiﬁc clinical studies and
were never intended for diagnostic use.
Consequently, there remains a need for ﬁrm diag-
nostic criteria for routine clinical use, which may
diﬀer from these.
The criteria for the laboratory diagnosis of APS
remain controversial. It has been proposed by some
that the Sydney laboratory criteria should be mod-
iﬁed such that testing for ab2GPI should be limited
to measurements of IgG ab2GPI only and testing
for aCL should be omitted.
2 The basis for this is
that in a systematic review, LA showed the highest
strength of association with thrombotic complica-
tions
3,4 and IgG but not IgM ab2GPI was asso-
ciated with thrombosis. In addition, Opatrny
et al. reported in a meta-analysis that LA was
also most strongly associated with late (>13 and
<24 weeks) recurrent fetal loss.
4 Galli et al.
3 also
drew attention to the need to produce guidelines,
which were subsequently published,
5 attempting to
standardize more clearly the criteria for the detec-
tion of LA.
Others have argued that it is premature to con-
sider reducing the number of assays used in the
diagnosis of APS. The systematic review by Galli
et al.
3 referred to above also suggested that
medium- or high-titre IgG aCL may represent a
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have previously reported that omission of aCL test-
ing from the clinical investigation of APS could
lead to a failure to diagnose the syndrome in a
proportion of patients,
6–8 and, in a multicentre pro-
spective European women cohort, isolated aCL
and/or ab2GPI positivity was found in a proportion
of women with obstetric APS.
7 The cut-oﬀ for sero-
logical positivity is also contentious. It has been
reported that women with obstetric APS (without
systemic thromboembolism) have lower aCL anti-
body titres than patients with a thrombotic his-
tory.
9 Data from a retrospective cohort study
10
and also in the prospective European cohort
7 sug-
gest that low-titre aCL, deﬁned as those between
the 95
th and 99
th percentiles rather than the 99
th
percentile as suggested in the ICS criteria, are
of clinical signiﬁcance for women with purely
obstetric APS.
Wahl et al. suggested that modiﬁcations of the
serological criteria for the diagnosis of APS should
in the future be based on new data and on appro-
priate systematic reviews.
8 The proposed entity of
seronegative APS, where patients have characteris-
tic clinical manifestations of APS but lack conven-
tional serological markers, has also been given
consideration in classiﬁcation criteria for APS.
11
We report on serological criteria in a cohort of
patients diagnosed to have APS, based on a com-
prehensive methodological approach which




We audited data on routine aPL testing retrospect-
ively from a cohort of 193 consecutive patients
attending the thrombosis and haemostasis, recur-
rent miscarriage or high-risk antenatal clinics at
UCLH, who had persistent aPL positivity based
on testing for LA, IgG and IgM aCL and ab2GPI
on two or more consecutive occasions at least 12
weeks apart. Case ascertainment was based on
review of the clinic letters of all patients attending
the clinics speciﬁed above. These clinic letters were
saved prospectively in a dedicated area on the hos-
pital electronic records system so that they were all
immediately retrievable.
In patients with thrombotic APS, high-risk
patients have been recognized in the literature to
include those who experience recurrent venous
events or arterial thrombosis.
12,13 However, there
are no agreed published deﬁnitions for the categor-
ization of the clinical severity of thrombotic, or
obstetric, APS. In this audit, high-risk APS was
deﬁned as the presence of any of the following clin-
ical scenarios: recurrent objectively diagnosed
thrombotic events; thromboses in both venous
and arterial sites; both early and late pregnancy
morbidity as deﬁned in the Sydney clinical criteria
for APS
1; both pregnancy morbidity and throm-
botic events; and/or thrombosis or pregnancy mor-
bidity whilst receiving anticoagulant therapy.
The remainder were categorized as lower-risk.
Venous blood for LA was collected into 5ml
tubes containing one-tenth volume 0.105M tri-
sodium citrate (e.g. Vacutainer, Becton
Dickinson, Plymouth, UK) using 19 or 21 gauge
needles and minimal stasis. For LA, platelet-poor
plasma was prepared by double centrifugation at
room temperature at 2000g for 15 minutes, and
frozen in aliquots at  80 C until assayed. ab2GPI
antibodies and aCL were performed on serum.
Antiphospholipid antibody assays
All patients in the study cohort had persistent aPL–
that is, aPL were present on two or more consecu-
tive occasions at least 12 weeks apart.
aCL assays were performed using an in-house
assay employing 10% fetal calf serum as a blocking
agent
14 based on the work of Loizou et al.
15 and
standardized using the polyclonal ‘Harris’ stand-
ards.
15,16 The Sydney laboratory criteria state that
medium- or high-titre aCL are those above the 99
th
percentile or 40GPLU/MPLU. In this study, aCL
positivity was deﬁned as: medium/high titre (99
th
percentile) >20GPLU/MPLU; low-titre (95–99
th
percentile) IgG>5GPLU/MPLU. For patients
with thrombotic APS, the 99
th percentile cut-oﬀ
was used to deﬁne aPL positivity. However, a
number of studies have suggested the 99
th percent-
ile is too insensitive for clinical use for women with
fulﬁlling Sydney clinical criteria for obstetric APS
(and no systemic thrombotic manifestations)
7,9,10,17
so the 95
th percentile value was used to deﬁne in
these patients.
b2GPI were measured using a commercial kit
(Axis; Shield Diagnostics, Dundee, UK), based on
a method developed in our department.
18 ab2GPI
positivity was deﬁned as: low-titre (95–99
th percent-
ile) IgG>3.5units, IgM>3.0units; medium/high-
titre (99
th percentile) >15units.
Reference ranges for aCL and a 2GPI were obtained from
240 normal healthy volunteers LA testing and deriv-
ation of the local reference range were performed
according to ISTH
19 and BCSH guidelines
20 cur-
rent at that time, prior to publication of the
updated ISTH criteria.
5 Brieﬂy, samples were
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time (Pathromtin SL; Dade Behring, Marburg,
Germany) and appropriate mixing studies. LA
activity was conﬁrmed using a dilute Russell’s
viper venom time (DRVVT) employing a platelet
neutralization procedure (Pathway Diagnostics,
Dorking, UK). Patients receiving warfarin were
tested using the Taipan venom time as previously
described.
20,21 All patients had at least one DRVVT
performed whilst not receiving warfarin.
Statistical analysis
Non-parametric statistical methods were used
throughout. The Mann–Whitney U test was used
to test for statistically signiﬁcant diﬀerences
between medians. Linear-by-linear association was
assessed using the Mantel–Haenszel chi-squared
test. Statistical signiﬁcance was deﬁned as
p<0.05. Statistical analyses were performed using
SPSS 16.0 (SPSS Inc. Chicago, IL).
Results
Figure 1 shows a ﬂowchart of patient selection
according to Sydney clinical criteria for APS, with
clinical diagnoses summarized here. One hundred
and forty-ﬁve of the cohort of 193 patients had
the following clinical manifestations which fulﬁlled
the Sydney clinical criteria 1: thrombosis (total 91;
arterial 33; venous 48; both arterial and venous 10);
early and/or late pregnancy morbidity as deﬁned in
the Sydney clinical criteria for APS (54), with 14 of
these 54 exhibiting both thrombotic and obstetric
manifestations. Nineteen of the 145 had underlying
autoimmune disease (including 11 with systemic
lupus erythematosus (SLE), two of whom also
had ITP, and a further two with ITP). The remain-
ing 48 of the 193 patients, who did not meet the
Sydney clinical criteria, had the following diag-
noses: immune thrombocytopenia (6), dystonia
(4), migraine (12), multiple sclerosis (3), dementia
(1), leprosy (1) or SLE (1). Eight were referred with
a history of obstetric morbidity which did not meet
the Sydney criteria and 12 were asymptomatic.
These 48 patients will not be discussed further.
The distribution of aPL positivity is summarized
in Figure 2 and by clinical diagnoses in Table 1. Of
the 145 patients who fulﬁlled the Sydney clinical
criteria for APS, 100 also fulﬁlled the Sydney
laboratory criteria; that is, if aCL and/or ab2GPI
were present their levels were greater than the 99
th
percentile. A further 26 women who fulﬁlled clin-
ical criteria for purely obstetric APS (and without a
Figure 1 Flowchart showing patient selection according to Sydney clinical criteria for APS.
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and/or ab2GPI; that is, above the 95
th percentile
but below the 99
th percentile, in the absence of
LA. Thus a total of 126/145 patients were con-
sidered to have APS according to our local criteria.
Sixty-seven of these 126 patients were LA-negative,
of whom 12 had aCL positivity only, 37 had
ab2GPI positivity only, and 18 were positive for
both aCL and ab2GPI. Consequently, omission of
aCL or ab2GPI from the laboratory investigation
of APS would have resulted in the failure to diag-
nose APS in 9.5% and 29.4% of patients, respect-
ively. Twenty-two of these 67 patients had high-risk
APS as deﬁned in the Methods section above, of
whom 11.5% had single positivity for ab2GPI or
aCL. IgM aCL and/or ab2GPI antibodies (1 aCL,
25 ab2GPI, 3 aCL and ab2GPI), alone or in asso-
ciation with IgG antibodies, were found in 53.7%
(29/54) of women who fulﬁlled Sydney clinical cri-
teria for purely obstetric APS.
IgG aCL and IgM aCL levels (Figure 3) and IgM
ab2GPI levels (Figure 4) were signiﬁcantly higher in
patients with a history of thrombosis than in
women with a history of purely obstetric APS
(p<0.05). Similarly the rate of LA positivity was
also signiﬁcantly higher in patients with a history of
thrombosis compared with those with obstetric
APS alone (50.5% v 15%; p¼0.0002).
High-risk APS, as deﬁned in the Methods sec-
tion, was observed in 60 of the 145 (41%) patients
fulﬁlling the Sydney clinical criteria for thrombosis
or obstetric APS. The number of positive tests (as
deﬁned by the Sydney laboratory criteria) was sig-
niﬁcantly associated with clinical severity in
patients who fulﬁlled both clinical and laboratory
Sydney criteria: 42.2% with one positive test,
41.2% with two positive tests; and 64.7% with
three positive tests (p¼0.026). In contrast, only
30.0% of patients with low-titre aPL alone had a
clinical history consistent with high-risk APS as
deﬁned in the Methods section.
With regard to the association between positivity
for a single aPL test and severity of APS, only the
incidence of LA (50.0%v 31.8%, p<0.05) and
median titre of IgM aCL (Figure 5) were associated
with high-risk APS in this cohort. Twenty-ﬁve out
of 54 (46.3%) women with a history of pregnancy
morbidity had clinical histories consistent with
high-risk APS (as deﬁned in the Methods section)
compared to 7/26 (26.9%) of the same group who
had low-titre APL.
Discussion
We report the clinical and laboratory ﬁndings of a
cohort of 193 patients who had persistently positive
tests for aPL. One hundred of these 193 patients
had APS as deﬁned by Sydney clinical as well as
laboratory criteria
1; and 126 when women with
purely obstetric APS (without a history of throm-
bosis) associated with low-titre aCL and/or ab2GPI
were also included as suggested in a number of
other studies7,9,10,17 although not included in
the Sydney laboratory criteria for APS.1.
Our data indicate that omission of testing for
aCL or ab2GPI from the clinical investigation of
APS would have led to a failure to diagnose the
syndrome in 9.5% and 29.4% of patients respect-
ively. Although the term high-risk in relation to
patients with thrombotic APS now appears in the
literature,
12,13,22 there are no agreed published def-
initions for this term in thrombotic or obstetric
APS. To assess the clinical relevance of persistent
aPL in our cohort, as it is possible that these per-
sistent aPL could have occurred by chance, we cate-
gorized patients in our cohort as having high-risk or
lower-risk APS as detailed in the Methods section
and correlated aPL results with clinical risk. We
found, in agreement with previous reports, that
LA as well as triple positivity (that is, aCL,
23
ab2GPI and LA) were associated with high-risk
APS.
3,22,24,25 Furthermore, 11.5% of patients with
single positivity for ab2GPI or aCL (including IgM
aCL) had high-risk APS, highlighting the
Figure 2 Distribution of antiphospholipid positivity in
126 patients with antiphospholipid syndrome as detailed
in Figure 1.
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nosis of APS, as previously reported.
7,26 28
Over 50% of women with clinical features of
obstetric APS, but no thrombosis, had low-titre
aCL and/or ab2GPI in the absence of LA.
Approximately 27% of these patients had clinical
features of high-risk APS. The association of low-
titre aCL or ab2GPI in women with clinical features
consistent with Sydney clinical criteria for obstetric
APS could have arisen by chance; however, our
ﬁndings concur with those of Ruﬀati et al.
9 who
reported that the rate of aCL values between the
99th percentile and 40 GPL units was signiﬁcantly
higher (p<0.0001) in patients with pregnancy mor-
bidity (73.7%) as compared to those with vascular
thrombosis (16.9%) and those with both conditions
(16.7%), and concluded that the 99th percentile
cut-oﬀ level appears more sensitive than the
>40GPL value for the diagnosis of APS in
women with persistent aCL positivity alone asso-
ciated with obstetric APS. Low-titre aCL or
ab2GPI, in some cases occurring as an isolated phe-
nomenon, also appeared to be clinically signiﬁcant
in an analysis of laboratory ﬁndings in a
Figure 3 Anticardiolipin (aCL) results by clinical history. Pregnancy morbidity (n¼40), Thrombosis (n¼105, including 14 with
both thrombosis and pregnancy morbidity). All aCL values above the 95
th percentile are shown. Horizontal bars represent the
median titres.
Table 1 The distribution of antiphospholipid positivity by clinical diagnoses









IgG ab2GPI 4 (10.0%) 6 (15.0%) 30 (28.6%) 40 (38.1%)
IgM ab2GPI 6 (15.0%) 23 (57.5%) 25 (23.8%) 59 (56.2%)
IgG aCL 4 (10.0%) 13 (32.5%) 23 (21.9%) 45 (42.9%)
IgM aCL 0 (0.0%) 4 (10.0%) 10 (9.5%) 21 (20.0%)
LA positivity 6 (15.0%)
b 53 (50.5)
b
aIncludes 14 women with both thrombosis and pregnancy morbidity.
The number (percentage) of positive tests and median antibody levels (>99
th or>95
th<99
th percentile) are given or each clinical group.
bChi-squared: patients with pregnancy morbidity versus those with thrombosis p¼0.0002.
ab2GPI: anti-beta2 glycoprotein-1 antibodies; aCL: anticardiolipin antibodies; LA: lupus anticoagulant.
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n¼60. Horizontal bars represent the median titres.
Figure 4 anti-b2glycoprotein-1 (ab2GPI) results by clinical history. Pregnancy morbidity (n¼40), thrombosis (n¼105, including
14 with both thrombosis and pregnancy morbidity). All ab2GPI values above the 95
th percentile are shown. Horizontal bars
represent the median titres.
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obstetric APS.
7 Furthermore, in clinical studies,
persistent low-titre aCL were associated with a
>90% fetal loss rate in untreated pregnancies of
women with recurrent miscarriage and aPL, and
with signiﬁcantly improved pregnancy outcome fol-
lowing treatment with low-dose aspirin or heparin
and aspirin.
10,29–31 Our data also support the inclu-
sion of low-titre IgG and IgM aCL and ab2GPI
antibodies in the diagnosis of APS in women with
a history of clinical obstetric APS, where accurate
diagnosis has therapeutic implications during preg-
nancy with potentially far-reaching adverse clinical
consequences in an infant who may suﬀer long-
term physical disability and mental impairment as
a result of placental-mediated obstetric morbidity
such as intrauterine growth restriction, early onset
pre-eclampsia or placental insuﬃciency/abruption.
The pattern of aPL positivity in our cohort diﬀers
from that in some published cohort studies. There
may be several reasons for this. First, the aCL
ELISA used in this study does not contain add-
itional puriﬁed b2GPI and uses fetal calf serum as
ablocking agent.Despiteeﬀortstostandardize solid
phase assays for aCL, agreement between labora-
tories remains poor.
32,33 The source of cardiolipin
and technique used to coat the microtitre plates is
known to aﬀect results.
33 Some methods employ
fetal calf serum as a blocking agent, while others
use cardiolipin saturated with human b2glyco-
protein-1 as the solid phase antigen. The situation
for ab2GPI antibody tests is marginally better, with
someagreement between mostassays.
34,35 However,
diﬀerent b2GPI puriﬁcation methods are known to
give rise to inter-assay variation.
35,36 It should be
noted that when human b2GPI is added to aCL
assays there is understandably a high degree of
agreement between aCL and ab2GPI assays
37 and
this may have led to the suggestion that ab2GPI
are not present in patients who are negative for
aCL. Conversely, some have argued that aCL
assays detect clinically signiﬁcant antibodies which
are not detected by ab2GPI assays.
4,6,7 Secondly, a
signiﬁcant proportion of our cohort (37%) had
purely obstetric APS whereas many published stu-
dies have included only patients with a history of
thrombosis. Much of the published literature on
aPL phenotypes in APS relates to patients with
SLE-associated APS, whereas in the patients in
our cohort only a minority (19/145) had SLE, as
the study cohort comprised patients who had pre-
dominantly presented to haematology rather than
rheumatology clinics.
In selecting the 95
th percentile as a cut-oﬀ value
for aCL and ab2GPI in purely obstetric APS, a
small number of false positives are likely to result.
However, if the 99
th percentile were used as a cut-
oﬀ in these women, many cases of obstetric APS
are likely to be missed. The role of IgM ab2GPI
testing in the diagnosis of APS remains unclear
and it considered to have little clinical utility for
thrombotic APS.
38 In our cohort >50% of
women with obstetric APS had low-titre IgM aCL
and/or ab2GPI (alone or in association with IgG
antibodies). Given the favourable risk/beneﬁt
ratio of heparin/aspirin treatment during preg-
nancy for obstetric APS it appears reasonable, at
present, to oﬀer this treatment during pregnancy to
women with low-titre aPL associated with obstetric
APS. However, future studies into the clinical sig-
niﬁcance and management of low-titre aPL in
obstetric APS would be useful.
In conclusion, these data suggest that LA, IgG
and IgM aCL and ab2GPI testing are all required
for the accurate diagnosis and assessment of prog-
nosis of APS in routine clinical practice.
Furthermore, as laboratory tests for aPL remain
poorly standardized internationally, it is prudent
to retain testing for LA as well as aCL and
ab2GPI for APS diagnosis. Our data also suggest
that low-titre aCL and ab2GPI should be included
in the laboratory criteria for diagnosis of purely
obstetric APS. This should be validated in a pro-
spective multicentre study.
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